MANEVeradermics Inc
$91.69
$9.54
(9.42%)
Closed $91.69
$0.31
(0.34%)
After Hours
EarningsAug 13
Mkt Cap$3.83B
Vol548,758.00
Fundamentals
Mkt Cap
$3.83B
Volume
-
52W High
$117.71
52W Low
$17.00
PE Ratio
-
Avg. Volume
568,136.97
EPS (Annual)
-$2.23
Rev/Employee
$0.00
Earnings
Aug 13
Veradermics to Present at Upcoming June Investor Conferences
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June...
Business Wire
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 302 Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 302 Study of VDPHL01 will be presented at the 2026 World Congress...
Business Wire
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
Key PointsSiren initiated a new position by acquiring 1,505,374 shares of Veradermics; the estimated transaction value is $75.94 million based on quarterly average pricing...
Nasdaq News: Markets
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced...
Business Wire
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported...
Business Wire
Citi Remains Bullish on Veradermics, Incorporated (MANE)
Citi Remains Bullish on Veradermics, Incorporated (MANE...
Yahoo! Finance: News
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill
Veradermics reported positive top line results from Part A of its Phase II/III 302 trial evaluating VDPHL01, an oral extended-release minoxidil tablet, in men with mild to moderate pattern hair loss...
MarketBeat
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Veradermics, Incorporated (Veradermics) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...
Business Wire
Veradermics Announces Launch of Public Offering
Veradermics, Incorporated (Veradermics) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...
Business Wire
Veradermics says its hair loss pill passed a late-stage trial, potentially the first oral treatment approved in 30 years
The extended-release minoxidil tablet could be the first FDA-approved oral treatment for pattern hair loss in about 30 years...
Quartz
<
1
2
...
>
Advertisement|Remove ads.
Latest MANE News
ViewVeradermics to Present at Upcoming June Investor Conferences
Business Wire
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 302 Study of VDPHL01 at the 2026 World Congress for Hair Research
Business Wire
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
Nasdaq News: Markets
Advertisement|Remove ads.